Alivus Life Sciences Limited
All news and filings related to Alivus Life Sciences Limited.
View all news & filings- Medium impact
Alivus Life Sciences Holds 15th AGM on Sep 8, 2026; Approves Dividend & Director Re-appointment
Alivus Life Sciences Limited held its 15th AGM on September 8, 2026. The company declared a final dividend of ₹5 per equity share for FY26 and re-appointed Mr. Hiren Patel as a Director. The audited financial statements for FY26 were approved, and the remuneration of the Cost Auditor for FY27 was ratified.
Read the summary - Low impact
Alivus Life Sciences to Hold Investor/Analyst Meetings on Sep 10-11, 2026
Alivus Life Sciences Limited will conduct investor and analyst meetings on September 10 and 11, 2026, in Mumbai. The meetings will be held in-person and will involve various Mutual Funds and Institutions.
Read the summary - Low impact
Alivus Life Sciences to Hold Investor Meetings on September 9, 2026
Alivus Life Sciences Limited will conduct one-on-one investor and analyst meetings in Mumbai on September 9, 2026. Participants include Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital. The meetings are in-person.
Read the summary - Low impact
Alivus Life Sciences to Hold Investor/Analyst Meetings from Aug 28 to Sep 2
Alivus Life Sciences will conduct investor and analyst meetings from August 28 to September 2, 2026. Meetings include virtual sessions with Mirae Asset (US) and Lyptus Capital, and in-person meetings in Mumbai with Emkay Global and SIMPL.
Read the summary - Medium impact
Alivus Life Sciences Acquires 76% Stake in IQGenX Pharma for ₹91.2 Million
Alivus Life Sciences acquired a 76% stake in IQGenX Pharma for ₹91.2 million. IQGenX specializes in formulation development for oral solids, sterile injectables, and ophthalmics. This acquisition expands Alivus's capabilities into advanced formulation and regulatory filings, targeting global generic pharmaceutical markets.
Read the summary - Medium impact
Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma for ₹9.12 crore
Alivus Life Sciences will acquire a 76% stake in IQGEN-X Pharma for approximately ₹9.12 crore. IQGEN-X Pharma, with FY26 turnover of ₹348 Lacs, develops oral solids, sterile injectables, and ophthalmic solutions. The acquisition aims to expand Alivus's API and CDMO offerings. Completion is expected by December 6, 2026.
Read the summary - Low impact
Alivus Life Sciences Releases Business Responsibility & Sustainability Report for FY 2025-26
Alivus Life Sciences Limited has released its Business Responsibility & Sustainability Report for FY 2025-26. The report highlights the company's ESG initiatives, including goals for Water Neutrality by 2027 and Carbon Neutrality by 2030. It details efforts in environmental management, employee welfare, and supply chain integrity.
Read the summary - Medium impact
Alivus Life Sciences Announces 15th AGM on Sep 8, 2026, with ₹5 Dividend
Alivus Life Sciences will hold its 15th AGM on September 8, 2026, via VC/OAVM. The company proposes a final dividend of ₹5 per equity share for FY26. Mr. Hiren Patel's re-appointment as director and ratification of cost auditor remuneration are also on the agenda. E-voting is open from Sep 4-7, 2026.
Read the summary - Low impact
Alivus Life Sciences to Meet SBI Mutual Fund on August 12, 2026
Alivus Life Sciences Limited will hold an in-person one-on-one meeting with SBI Mutual Fund on August 12, 2026, in Mumbai. The schedule may change due to exigencies.
Read the summary - Low impact
Alivus Life Sciences to Attend Emkay Confluence Investor Meet on Aug 12, 2026
Alivus Life Sciences Limited will attend the Emkay Confluence investor meet on August 12, 2026, in Mumbai. The meeting will consist of group and one-on-one interactions. The company has notified exchanges as per SEBI regulations.
Read the summary - Medium impact
Alivus Life Sciences Q1 FY'27 Earnings Call Transcript Released
Alivus Life Sciences reported Q1 FY'27 revenues of ₹640 crore, up 6.4% YoY, driven by 26.5% growth in non-GPL business. Gross margins improved to 60.2% and EBITDA margins to 36.6%. The company guides for 10-12% revenue growth in FY'27, skewed towards H2, and expects to maintain EBITDA margins of 30-32%. Solapur facility operational in early Q3 FY'27.
Read the summary - Medium impact
Alivus Life Sciences Announces 15th AGM on September 8, 2026
Alivus Life Sciences will hold its 15th AGM on September 8, 2026, via video conference. The company reported consolidated revenue of ₹1,817.66 crore and profit after tax of ₹583.26 crore for Q1 FY27. Standalone revenue was ₹5,543.66 crore with PAT of ₹1,215.55 crore.
Read the summary - Medium impact
Alivus Life Sciences Sets Sept 1 as Record Date for ₹5 Dividend, AGM on Sept 8
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The record date for a ₹5 per equity share final dividend for FY26 is set for September 1, 2026. Dividend payments are expected on or after September 11, 2026, subject to AGM approval.
Read the summary - Medium impact
Alivus Life Sciences Announces 15th AGM on Sep 8, 2026, with Dividend Payout
Alivus Life Sciences will hold its 15th AGM on September 8, 2026, to approve a final dividend of ₹5.00 per equity share for FY26. The record date for dividend entitlement is September 1, 2026. Dividend payments are expected on or after September 11, 2026.
Read the summary - Low impact
Alivus Life Sciences Uploads Q1 FY27 Earnings Call Audio Recording
Alivus Life Sciences Limited has uploaded the audio recording of its Q1 FY2027 Earnings Call, which took place on July 31, 2026. The recording is accessible on the company's official website.
Read the summary - Low impact
Alivus Life Sciences Allots 32,000 Shares Under ESOP, Paid-up Capital Rises
Alivus Life Sciences approved the allotment of 32,000 equity shares under its ESOP scheme on July 30, 2026. This increases the company's paid-up share capital to 12,27,71,448 equity shares, amounting to ₹24,55,42,896.
Read the summary - Medium impact
Alivus Life Sciences Q1 FY27 Investor Presentation Showcases Robust Growth
Alivus Life Sciences reported Q1 FY27 revenue of ₹6,404 million and EBITDA of ₹2,341 million. The non-GPL business grew 26.5% YoY. The company projects 10%-12% revenue growth for FY27 with EBITDA margins of 30%-32%. Capacity expansions are planned through FY29.
Read the summary - High impact
Alivus Life Sciences Q1FY27 PAT Grows 32% YoY to ₹160 Crore, Revenue Up 6.4%
Alivus Life Sciences reported Q1FY27 results with PAT growing 31.8% YoY to ₹1,601 million and revenue up 6.4% YoY to ₹6,404 million. EBITDA margins reached 36.6%. The company expects FY27 revenue growth of 10%-12% and maintains EBITDA margins of 30%-32%. Capex includes facility expansions in Solapur and a new R&D centre in Taloja.
Read the summary - Medium impact
Alivus Life Sciences Q1 FY27 Net Profit at ₹160.08 Crore, Revenue at ₹662.82 Crore
Alivus Life Sciences reported Q1 FY27 results with total income at ₹662.82 crore and net profit at ₹160.08 crore. Basic EPS stood at ₹13.04. The results were approved by the Board on July 30, 2026.
Read the summary - Low impact
Alivus Life Sciences to hold Q1 FY26-27 Earnings Call on July 31, 2026
Alivus Life Sciences Limited will conduct its Q1 FY2026-27 earnings call on July 31, 2026, from 8:30 AM to 9:30 AM IST. Dial-in details and pre-registration information are provided.
Read the summary - Medium impact
Alivus Life Sciences to consider Q1 FY27 results on July 30, 2026; trading window closed
Alivus Life Sciences will hold a board meeting on July 30, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The trading window for designated persons is closed from July 1, 2026, to August 1, 2026.
Read the summary - Low impact
Alivus Life Sciences to Hold Analyst/Institutional Investor Meeting on June 16
Alivus Life Sciences Limited will conduct an in-person one-on-one meeting with Aditya Birla SunLife MF on June 16, 2026, in Mumbai. The company noted that the meeting schedule and mode may change.
Read the summary - Low impact
Alivus Life Sciences to Attend Investor Meetings from June 9, 2026
Alivus Life Sciences Limited will attend investor and analyst meetings starting June 9, 2026, in Mumbai. The meetings will be in-person and include participants like Alchemy Group, ASK Mutual, and SBI MF. The schedule may change.
Read the summary - Medium impact
Alivus Life Sciences Releases Q4 FY26 Earnings Call Transcript
Alivus Life Sciences reported Q4 FY26 revenue of ₹689 crore and full-year revenue of ₹2,552 crore, up 6.1% and 6.9% YoY respectively. EBITDA margins reached 33.6% for the full year, driven by non-GPL segment growth and operational efficiencies. The company plans ₹540 crore capex in FY27, funded internally, and expects to maintain EBITDA margins of 30-32%.
Read the summary - Low impact
Alivus Life Sciences to Meet Ambit India, Abakkus Asset Managers on May 25 & 27
Alivus Life Sciences will participate in investor meetings on May 25, 2026, with Ambit India at the Titans of Tomorrow Conference and on May 27, 2026, with Abakkus Asset Managers. Both meetings will be held in-person in Mumbai.
Read the summary - Low impact
Alivus Life Sciences Intimates Analyst/Institutional Investor Meeting on 22 May 2026
Alivus Life Sciences will conduct a virtual one-on-one meeting with Karma Capital on May 22, 2026, for analysts and institutional investors. The meeting's schedule and mode are subject to change.
Read the summary - Low impact
Alivus Life Sciences Uploads Q4 & FY26 Earnings Call Audio Recording
Alivus Life Sciences has uploaded the audio recording of its Q4 and FY2025-26 Earnings Call, which took place on May 15, 2026. The recording can be accessed on the company's website.
Read the summary - High impact
Alivus Life Sciences FY26 Revenue up 6.9% to ₹25,518 crore, EBITDA up 19.6%
Alivus Life Sciences reported FY26 revenue of ₹25,518 million, up 6.9% YoY, and EBITDA of ₹8,577 million, up 19.6% YoY. PAT rose 16.2% to ₹5,645 million, with EPS at ₹45.99. The non-GPL business grew 13%, contributing 71% of revenue. For FY27, high single-digit revenue growth and margins above 30% are projected.
Read the summary - High impact
Alivus Life Sciences FY26 Revenue Up 6.9% to ₹2,551.8 Crore; EBITDA Margins at 33.6%
Alivus Life Sciences reported FY26 revenue of ₹2,551.8 crore, up 6.9% YoY. EBITDA grew 19.6% to ₹857.7 crore with margins at 33.6%. PAT increased 16.2% to ₹564.5 crore. The company expects high single-digit revenue growth and sustained margins above 30% for FY27.
Read the summary - Medium impact
Alivus Life Sciences Recommends Final Dividend of ₹5/Share; Q4FY26 Profit ₹162.61 Crore
Alivus Life Sciences reported audited financial results for FY26. The company recommended a final dividend of ₹5 per share. For Q4FY26, total income was ₹711.89 crore and profit after tax was ₹162.61 crore. For the full year FY26, profit after tax was ₹564.48 crore.
Read the summary - Medium impact
Alivus Life Sciences Recommends Final Dividend of ₹5/Share; Reports FY26 Audited Results
Alivus Life Sciences reported audited results for FY26. The company recommended a final dividend of ₹5 per share. The Board of Directors met on May 14, 2026, to approve the results and dividend recommendation.
Read the summary - Low impact
Alivus Life Sciences Schedules Q4 FY26 Earnings Call for May 15
Alivus Life Sciences will host its Q4 FY26 and FY26 earnings call on May 15, 2026, from 8:30 to 9:30 AM IST. The call will discuss the company's financial performance for the period. Dial-in details and pre-registration links are provided.
Read the summary - Medium impact
Alivus Life Sciences Announces Board Meeting on May 14, 2026, for Audited Financial Results and Dividend Recommendation
Alivus Life Sciences will hold a Board Meeting on May 14, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The Board will also consider recommending a dividend for the financial year. The trading window is closed from April 01 to May 16, 2026.
Read the summary - Low impact
Alivus Life Sciences Receives ₹2.6 Crore Tax Demand Order from Income Tax Dept.
Alivus Life Sciences received a ₹2.6 crore tax demand order from the Income Tax Department for AY 2023-24. The demand is due to disallowances of expenditure. The company believes there is no material financial or operational impact and plans to appeal the order.
Read the summary - Low impact
Alivus Life Sciences to Meet Millennium Capital Management on March 17, 2026
Alivus Life Sciences Limited will hold an in-person 'One on One' meeting with Millennium Capital Management on March 17, 2026, in Mumbai. This disclosure is in accordance with SEBI regulations.
Read the summary - Low impact
Alivus Life Sciences to Hold Investor Meetings from March 12-16, 2026
Alivus Life Sciences will conduct investor and analyst meetings from March 12 to March 16, 2026. The schedule includes virtual one-on-one meetings with ICICI Direct on March 12, and in-person meetings in Mumbai with Green Lantern Capital and S Four Capital on March 16. The company noted that schedules may change.
Read the summary - Medium impact
Alivus Life Sciences Expects API Production to Resume by 1 March 2026 After Fire Incident
Alivus Life Sciences reports that a fire incident on February 14, 2026, at its Dahej facility affected one production block, but API manufacturing was unaffected. API production is expected to resume by March 1, 2026, and intermediate production by mid-March 2026. The company anticipates a few delayed shipments due to this temporary disruption.
Read the summary - Medium impact
Alivus Life Sciences API Plant in Dahej Fire: Three Injured, Production Halted
A fire broke out at Alivus Life Sciences' API plant in Dahej on February 14, 2026, causing three injuries. Production has been temporarily halted. The company has adequate insurance coverage and is assessing the damage.
Read the summary - Low impact
Alivus Life Sciences to Attend Multiple Investor/Analyst Meets in February 2026
Alivus Life Sciences Limited will attend three investor and analyst meetings in February 2026. These include the MANTHAN conference on Feb 10, Nuvama conference on Feb 11, and Kotak conference on Feb 26, all in Mumbai. Meetings will be in-person and in group/one-on-one formats.
Read the summary - High impact
Alivus Life Sciences Q3 FY26 Earnings Call Transcript Released
Alivus Life Sciences reported highest-ever Q3 FY26 revenue of ₹673 crore, up 14.4% QoQ and 4.8% YoY. EBITDA margin reached 36.4%. The company expects high single-digit revenue growth for FY26 and maintained EBITDA margins of 30-32%. CAPEX guidance for FY26 revised to ₹450 crore.
Read the summary - Low impact
Alivus Life Sciences Receives Tax Appeal Order, Demand Reduced to ₹91.7 Lakhs
Alivus Life Sciences received a tax appeal order reducing its demand for FY 2019-20. The revised demand is ₹83.38 Lakhs plus ₹8.34 Lakhs penalty and interest, down from the original ₹5.21 Crore demand. The company assesses no material financial or operational impact and is considering further appeal.
Read the summary - Low impact
Alivus Life Sciences to Hold Multiple Investor Meetings in Early February 2026
Alivus Life Sciences Limited will conduct investor and analyst meetings from February 2 to February 4, 2026. Meetings will be virtual, with one in-person session in Mumbai on February 3. Participants include Catamaran, Vyom Partners, Choice India, Kosh Wealth Management, and Avendus Spark.
Read the summary - Low impact
Alivus Life Sciences Uploads Q3 FY26 Earnings Call Audio Recording
Alivus Life Sciences has uploaded the audio recording of its Q3 FY2025-26 Earnings Call held on January 22, 2026. The recording is accessible on the company's website as per SEBI regulations.
Read the summary - High impact
Alivus Life Sciences Q3FY26 Revenue up 4.8% YoY to ₹672.9 Crore; EBITDA Margins Expand 510 bps YoY
Alivus Life Sciences reported Q3FY26 revenue of ₹672.9 crore (up 4.8% YoY) and EBITDA of ₹245.2 crore (up 22.1% YoY). EBITDA margins expanded 510 bps YoY to 36.4%. CDMO revenues grew 85.3% YoY. For 9MFY26, revenue was ₹1,862.7 crore (up 7.2% YoY) and EBITDA margins improved by 400 bps YoY to 33.3%.
Read the summary - High impact
Alivus Life Sciences Reports Record Q3 FY26 Revenue of ₹6,729 Mn and EBITDA Margins of 36.4%
Alivus Life Sciences reported record Q3 FY26 revenues of ₹6,729 million (672.9 crore) and highest-ever EBITDA margins of 36.4%. For 9MFY26, revenues were ₹18,627 million (1,862.7 crore). PAT for Q3 FY26 reached ₹1,503 million (150.3 crore). The company generated ₹2,207 million (220.7 crore) in free cash flow and remains net debt-free.
Read the summary - Medium impact
Alivus Life Sciences Q3 FY26 Revenue at ₹672.88 Crore, Profit at ₹150.26 Crore
Alivus Life Sciences reported Q3 FY26 results with total income of ₹686.82 crore and profit after tax of ₹150.26 crore. For the nine months ended Dec 31, 2025, total income was ₹1,900.35 crore and profit after tax was ₹401.82 crore. EPS for the quarter was ₹12.25.
Read the summary - Low impact
Alivus Life Sciences Announces Q3 FY2025-26 Earnings Call on Jan 22, 2026
Alivus Life Sciences Limited has scheduled its Q3 FY2025-26 earnings call for January 22, 2026, from 6:00 PM to 7:00 PM IST. The company will discuss its financial performance. Dial-in details and pre-registration are available.
Read the summary - Low impact
Alivus Life Sciences Board Meeting on Jan 22, 2026, to Approve Q3 FY26 Results
Alivus Life Sciences will hold a Board Meeting on January 22, 2026, to approve unaudited financial results for the quarter and nine months ended December 31, 2025. The trading window is closed from December 31, 2025, to January 24, 2026.
Read the summary - Low impact
Alivus Life Sciences to Meet Kosh Wealth Management on Dec 30, 2025
Alivus Life Sciences Limited will hold a one-on-one meeting with Kosh Wealth Management in Mumbai on December 30, 2025. The meeting format is in-person.
Read the summary - Low impact
Alivus Life Sciences to Hold Investor Meetings on Dec 23 & Dec 29, 2025
Alivus Life Sciences Limited will conduct one-on-one investor meetings on December 23, 2025 (virtual with Omega Portfolio and Mount Intra Finance) and December 29, 2025 (virtual with Choice India, in-person with Centrum PMS in Mumbai).
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio